Stempeutics Research

Executive Summary

Stempeutics Research is a private Indian biotech company pioneering allogeneic mesenchymal stromal cell (MSC) therapies. Its lead product, Stempeucel®, is a shelf-stable, pooled MSC therapy already approved in India for knee osteoarthritis and critical limb ischemia, providing a commercial foundation and real-world validation of its platform. The company is expanding its pipeline into vascular complications, diabetic wounds, gastrointestinal disorders, and stem-cell-derived cosmetics, leveraging its proprietary manufacturing process to enable off-the-shelf availability. With over 15 years of research and a growing commercial presence, Stempeutics is positioned as a leader in regenerative medicine in emerging markets, while also exploring global opportunities through partnerships and regulatory filings. The company's focus on indications with high unmet need and its ability to deliver consistent, scalable cell therapy products underpin its growth strategy, though its private status limits public visibility into financials and pipeline progress.

Upcoming Catalysts (preview)

• Q4 2027FDA/EMA filing submission for Stempeucel in critical limb ischemia or osteoarthritis outside India40% success
• Q2 2027Phase II/III clinical data readout for Stempeucel in diabetic foot ulcers or inflammatory bowel disease50% success
• Q1 2027Out-licensing or distribution partnership for Stempeucel in Southeast Asia or Middle East60% success